Article
Urology & Nephrology
Georg R. Herrnstadt, Christoph B. Niehus, Torben Ramcke, Julia Hagenstein, Laura-Isabell Ehnold, Anna Nosko, Matthias T. Warkotsch, Frederic C. Feindt, Simon Melderis, Hans-Joachim Paust, Varshi Sivayoganathan, Saskia-Larissa Jauch-Speer, Milagros N. Wong, Daniela Indenbirken, Christian F. Krebs, Tobias B. Huber, Ulf Panzer, Victor G. Puelles, Malte A. Kluger, Oliver M. Steinmetz
Summary: Previous studies have identified a unique Treg population, known as RORyt+ Tregs, which possess enhanced immunosuppressive capacity and therapeutic potential. However, they are also capable of secreting pro-inflammatory IL-17A. This study investigated the absence of RORyt+ Tregs in glomerulonephritis (GN) and found that their absence significantly aggravated kidney injury, demonstrating their overall kidney-protective properties. Analyses showed that RORyt+ Tregs were broadly immunosuppressive, and their absence had a negative impact on GN.
KIDNEY INTERNATIONAL
(2023)
Review
Oncology
Jemmy Zhao, Susann Stephan-Falkenau, Markus Schuler, Boerge Arndt
Summary: This review discusses the recent advances in genetic and molecular characterization of combined hepatocellular-cholangiocarcinoma (cHCC-CC), a rare and aggressive liver tumor with features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). The optimal treatment for cHCC-CC has not been defined due to its rarity, but liver resection is the mainstay treatment for resectable disease. For advanced disease, there is a lack of guideline recommendations or prospective trial reports to evaluate treatment options. This review explores locoregional and medical treatment approaches for advanced cHCC-CC and discusses the potential of predictive biomarker-guided therapies.
Article
Cell Biology
Lisha Mou, Chenyang Jia, Zijing Wu, Boyang Xin, Carmen Alicia Liang Zhen, Bailiang Wang, Yong Ni, Zuhui Pu
Summary: This study established a robust CSIRG signature for HCC diagnosis using single-cell RNA-seq and bulk RNA-seq, revealing the correlation between three key immune-related genes and the overall survival of HCC patients, providing a new approach for evaluating the diagnosis and treatment of HCC patients.
Article
Oncology
Yulin Cao, Yuan Yin, Xue Wang, Zhifeng Wu, Yuhang Liu, Fuzheng Zhang, Junhua Lin, Zhaohui Huang, Leyuan Zhou
Summary: The research indicates that MMP-8 secreted by sublethal irradiated NPCs enhances the migration and invasion of HCC cells by regulating the AMPK/mTOR signaling pathway.
Article
Oncology
Luca Ielasi, Francesco Tovoli, Matteo Tonnini, Bernardo Stefanini, Raffaella Tortora, Giulia Magini, Rodolfo Sacco, Tiziana Pressiani, Franco Trevisani, Ingrid Garajova, Fabio Piscaglia, Alessandro Granito
Summary: This study aimed to evaluate the prognostic role of different sites of metastases in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. The results showed that lymph nodes and lung metastases were associated with worse survival rates and treatment response, while bone and adrenal gland metastases did not significantly impact prognosis. Therefore, targeted treatment strategies should be considered for different metastatic sites.
Article
Oncology
Sandra J. Casak, Martha Donoghue, Lola Fashoyin-Aje, Xiaoping Jiang, Lisa Rodriguez, Yuan-Li Shen, Yuan Xu, Xiling Jiang, Jiang Liu, Hong Zhao, William F. Pierce, Shubhangi Mehta, Kirsten B. Goldberg, Marc R. Theoret, Paul G. Kluetz, Richard Pazdur, Steven J. Lemery
Summary: The FDA approved atezolizumab in combination with bevacizumab for the treatment of unresectable hepatocellular carcinoma. The approval was based on Study IMbrave150 which showed improved overall survival and progression-free survival compared to standard care with sorafenib. Adverse reactions included hypertension, fatigue, and proteinuria.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Tao Liu, Qiao Shi, Lei Yang, Shusen Wang, Hongli Song, Zhenglu Wang, Xinnv Xu, Hongsheng Liu, Hong Zheng, Zhongyang Shen
Summary: The study identified characteristic alterations in lncRNA and mRNA expression in recurrent hepatocellular carcinoma (HCC) compared to primary HCC. Two upregulated lncRNAs, HERH-1 and HERH-4, were found to enhance cell proliferation and cell cycle progression in advanced HCC, with HERH-1 interacting with CREB1 to promote CCNA2 transcription and HERH-4 acting as a miR-29b/c sponge to facilitate CCNA2 protein translation.
Article
Oncology
Penella J. Woll, Piers Gaunt, Charlotte Gaskell, Robin Young, Charlotte Benson, Ian R. Judson, Beatrice M. Seddon, Maria Marples, Nasim Ali, Sandra J. Strauss, Alexander Lee, Ana Hughes, Baljit Kaur, David Hughes, Lucinda Billingham
Summary: Axitinib demonstrated anti-tumor activity in different subtypes of soft tissue sarcoma and had an acceptable adverse event profile. This study supports further investigation in phase III trials.
BRITISH JOURNAL OF CANCER
(2023)
Article
Gastroenterology & Hepatology
Yongkun Sun, Aiping Zhou, Wen Zhang, Zhichao Jiang, Bo Chen, Jianjun Zhao, Zhiyu Li, Liming Wang, Xinyu Bi, Hong Zhao, Kan Liu
Summary: This study shows that anlotinib is effective and safe as a first- or second-line treatment for advanced or metastatic hepatocellular carcinoma, with plasma CXCL1 potentially being a predictor for the efficacy of anlotinib.
HEPATOLOGY INTERNATIONAL
(2021)
Review
Oncology
Yingxuan Zhu, Yang Li, Weida Liu, Ruozhu Zhou, Lap Ah Tse, Yang Wang, Wei Li
Summary: This study conducted a network meta-analysis to assess the efficacy and safety of various pharmacotherapies for patients with metastatic, locally advanced, or recurrent breast cancer carrying BRCA1/BRCA2 pathogenic variants. The results showed that PARP inhibitors combined with platinum-based chemotherapy were the most effective treatment, but also posed an elevated risk of some adverse events.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Javier Gonzalez, Jeffrey J. Gaynor, Gaetano Ciancio
Summary: Renal cell carcinoma is now recognized as a group of different entities with unique molecular alterations requiring personalized systemic approaches. Current literature discusses recent advances in systemic therapy for metastatic RCC, along with challenges related to identifying biomarkers for treatment stratification. The development of new treatment agents based on RCC biology, transcriptomic analysis of the tumor microenvironment, and preclinical ex-vivo models to study immune-escape mechanisms are expected to improve treatment outcomes. New detection methods for tumor-circulating cells and imaging techniques will enhance identification of metastatic sites and response to treatment.
EXPERT REVIEW OF ANTICANCER THERAPY
(2021)
Article
Immunology
Vera Rebmann, Esther Schwich, Rafael Tomoya Michita, Lisa Gruentkemeier, Ann-Kathrin Bittner, Hana Rohn, Peter A. Horn, Oliver Hoffmann, Rainer Kimmig, Sabine Kasimir-Bauer
Summary: This study systematically evaluated the impact of HLA-G 3'UTR polymorphisms on disease status, presence of DTC, soluble HLA-G levels, and therapy and disease outcome in non-metastatic LABC patients. The results showed that specific UTR haplotypes were associated with tumor burden, presence of DTC, and therapy and disease outcome.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Ahmed Omar Kaseb, S. Cheenu Kappadath, Sunyoung S. Lee, Kanwal Pratap Raghav, Yehia Mohamed, Lianchun Xiao, Jeffrey S. Morris, Chimela Ohaji, Rony Avritscher, Bruno C. Odisio, Joshua Kuban, Mohamed E. Abdelsalam, Beth Chasen, Khaled M. Elsayes, Mohamed Elbanan, Robert A. Wolff, James C. Yao, Armeen Mahvash
Summary: The study conducted a prospective evaluation of sorafenib followed by Y-90 in patients with advanced HCC, confirming the safety of the treatment sequence and showing promising efficacy signals. This provides a proof of concept for potential future combination modalities for advanced or metastatic HCC patients.
JOURNAL OF HEPATOCELLULAR CARCINOMA
(2021)
Article
Oncology
Meenatai Naik, B. Vishal Rao, Daphne Fonseca, S. Sudha Murthy, Ashwin Giridhar, Rakesh Sharma, K. V. V. N. Raju, T. Subramanyeswar Rao, Sundaram Challa
Summary: The study observed the expression patterns of GATA-3 in primary and metastatic urothelial carcinomas of different grades and variants, showing that GATA-3 was positive in the majority of urothelial carcinoma cases and could be a useful marker for diagnosis.
INDIAN JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Seung-Hoon Beom, Ki Beom Bae, Dae Young Zang, Joohee Bae, In Gyu Hwang, Hye Jin Kang, In Sook Woo, Byoung Yong Shim, Byung-Noe Bae, Jaekyung Cheon, Sang-Bo Oh, Joong-Bae Ahn
Summary: This regulatory post-marketing surveillance study aimed to evaluate the safety and effectiveness of regorafenib in Korean patients with CRC, GIST, and HCC. The study found no new safety concerns and the results were consistent with previous clinical trials.
Article
Immunology
Hilal Uensal, Canan Caka, Hacer Neslihan Bildik, Saliha Esenboga, Alphan Kupesiz, Baris Kuskonmaz, Duygu Uckan Cetinkaya, Mirjam van Der Burg, Ilhan Tezcan, Deniz Cagdas
Summary: The study investigated the demographic, clinical, laboratory, follow-up, and treatment characteristics of 21 patients with Major Histocompatibility Complex Class II (MHC-II) deficiency. It was found that patients with Bare Lymphocyte Syndrome (BLS) exhibited clinical findings similar to severe combined immunodeficiency (SCID), and the flow cytometric MHC-II expression study played a crucial role in the diagnosis, differential diagnosis, early hematopoietic stem cell transplantation (HSCT), and post-HSCT follow-up.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
(2024)
Article
Immunology
Axel Rosell, Cecilia Karlstrom, Joakim S. Dahlin, Daryl Boey, Monika Klimkowska, Kajsa Ax, Charlotte Thalin, Johanna Ungerstedt
Summary: There is no evidence of global increase in neutrophil extracellular trap release in patients with systemic mastocytosis.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
(2024)
Article
Immunology
Charles W. Armitage, Connor P. O'Meara, Emily R. Bryan, Avinash Kollipara, Logan K. Trim, Danica Hickey, Alison J. Carey, Wilhelmina M. Huston, Gavin Donnelly, Anusch Yazdani, Richard S. Blumberg, Kenneth W. Beagley
Summary: This study demonstrates that IgG seroconversion during male infection can amplify female immunopathology and infertility. IgG transcytosis through the FcRn receptor allows Chlamydia to cross the epithelial barrier and be phagocytosed by antigen-presenting cells. This leads to increased pro-inflammatory signaling and T cell proliferation, resulting in more severe pathology and infertility in female mice.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
(2024)
Article
Immunology
Fatma Gonca Kocanci, Azize Yasemin Goksu Erol, Fatma Yildiz, Hamiyet Eciroglu
Summary: Calcineurin inhibitors, such as pimecrolimus, have been found to have preventive effects against neuroinflammation and apoptotic pathways, which are underlying mechanisms in neurodegenerative diseases. This study demonstrated that pimecrolimus exerts neuroprotective effects by inhibiting inflammation and oxidative stress, making it a potential treatment option for neurodegenerative diseases.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
(2024)